Menu Search
Equities

Alto Neuroscience Inc

ANRO:NYQ

Alto Neuroscience Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.92
  • Today's Change-0.515 / -3.83%
  • Shares traded229.31k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 18:33 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Alto Neuroscience Inc's net income fell 31.02% from a loss of 27.71m to a larger loss of 36.31m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, Alto Neuroscience Inc increased its cash reserves by 70.75%, or 34.20m. Cash Flow from Financing totalled 68.13m or -- of revenues. In addition the company used 33.45m for operations while cash used for investing totalled 470.00k.
Cash flow per share--
Price/Cash flow per share--
Book value per share6.67
Tangible book value per share6.67
More ▼

Balance sheet in USDView more

Alto Neuroscience Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio19.85
Quick ratio--
Total debt/total equity0.056
Total debt/total capital0.053
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.